Scheme of arrangement for amalgamation of Pavi Buildwell Private Limited (WOS) with Mankind Pharma Limited

Mankind/II,._ October 26, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Outcome of Board Meeting Ref.: Regulation 30, 33, 51 and 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) With reference to captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. Monday, October 26, 2026 have inter alia transacted the following business items: 1. Financial Results: Approved the unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2026. The copy of the said financial results along with Limited Review Report issued by M/s. S. R. Batliboi & Co. LLP, Chartered Accountants and M/s. Bhagi Bhardwaj Gaur & Co., Chartered Accountants, Joint Statutory Auditors of the Company, is enclosed herewith as Annexure-I; 2. Scheme of Amalgamation: i. Considered and approved the Scheme of Arrangement for amalgamation of Prolijune Lifesciences Private Limited (“Transferor Company 1”) and Pavi Buildwell Private Limited (“Transferor Company 2”), both being wholly owned subsidiaries of the Company, with and into Mankind Pharma Limited (“Transferee Company”/ “Company”) and their respective shareholders and creditors (“Scheme 1”/ “Scheme of Arrangement”), pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, read with the rules made thereunder. The Appointed Date for the Scheme of Arrangement is as defined therein i.e. April 01, 2027. In terms of Regulation 37(6) of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 and Joint Standard Operating Procedure (SOP) dated July 31, 2025 for application filed under regulation 59A of Listing Regulations, the Scheme 1, being an amalgamation of wholly owned subsidiaries with their holding company, is exempt from the requirement of obtaining a No-Objection Letter from the Stock Exchanges. However, as per requirement laid down in above provisions, the Company will file the Scheme of Arrangement with the Stock Exchanges for disclosure purposes. Further, the Scheme of Arrangement is subject to the necessary statutory and regulatory approvals including from the (i) shareholders and creditors (as may be required and/or to the extent not dispensed with by the relevant authorities); (ii) Hon’ble National Company Law Tribunal having jurisdiction over both the Transferor Companies and Transferee Company; and (iii) any other approvals, as may be required. ii. Considered and took note of the Scheme of Arrangement for amalgamation of Upakarma Ayurveda Private Limited (“Transferor Company” / “UAPL”) with and into Mankind Consumer Products MANKIND PHARMA LIMITED Regd. Office: 208, Okhla Ind. Estate, Phase -3, New Delhi-110020 •Ph.: 011-46846700, 47476600 CIN No. L74899DL 1991 PLC044843 •E-mail: contact@mankindpharma.com • www.mankindpharma.com Mankindl//lJJ,,. Private Limited (“Transferee Company” / “MCPPL”) (“Scheme 2”), as approved by the respective Boards of Directors of UAPL and MCPPL at their meetings held earlier today, as communicated by the said wholly owned subsidiaries to the Company today, i.e., October 26, 2026. MCPPL is a wholly owned subsidiary of the Company, while UAPL is a wholly owned subsidiary of MCPPL and accordingly, a step down wholly owned subsidiary of the Company. The proposed Scheme 2 is subject to receipt of requisite statutory, regulatory and other approvals, as may be applicable. The detailed disclosure for item Nos. 2(i) and 2(ii) as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026 is enclosed herewith as Annexure-II. Further, a certificate from the Joint Statutory Auditors of the Company pursuant to Regulation 54 read with Regulation 56(1)(d) of the Listing Regulations, 2015, and the applicable provisions of the SEBI Master Circular dated July 11, 2025, as amended from time to time, for the period ended September 30, 2026, is enclosed herewith as Annexure-III. The meeting of Board of the Company commenced at 01:45 p.m. (IST) and concluded at 02:45 p.m. (IST). You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a MANKIND PHARMA LIMITED Regd. Office : 208, Okhla Ind. Estate, Phase -3, New Delhi-110020 •Ph.: 011-46846700, 47476600 CIN No. L74899DL 1991 PLC044843 •E-mail : contact@mankindpharma.com • www.mankindpharma.com Annexure-I S.R. Batliboi & Co. LLP Bhagi Bhardwaj Gaur & Co. Chartered Accountants Chartered Accountants 67, Institutional Area, 2952-53/2, Sangatrashan Sector 44, D.B. Gupta Road, Gurugram - 122003, Haryana, India. Paharganj, New Delhi, India Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Mankind Pharma Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Mankind Pharma Limited (the "Company") for the quaiier ended September 30, 2026 and year to date from April 0 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Rep01iing" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Infom1ation Performed by the Independent Auditor of the Entity" issued by the Institute of Chaiiered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opm10n. 4. Based on our review conducted as above and based on the consideration of the review reports of respective auditors of 8 pa1inership foms refe1Ted to in paragraph 6 (a) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles [Showing first 8,000 characters — download PDF for full document]